IGF2 overexpression
|
CRC
|
IGF2 overexpression
|
CRC
|
cetuximab Sensitive: C3 – Early Trials
|
cetuximab Sensitive: C3 – Early Trials
|
IGF2 overexpression
|
HER2 Positive Breast Cancer
|
IGF2 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab Resistant: C3 – Early Trials
|
trastuzumab Resistant: C3 – Early Trials
|
IGF2 overexpression
|
HCC
|
IGF2 overexpression
|
HCC
|
BI-836845 Sensitive: D – Preclinical
|
BI-836845 Sensitive: D – Preclinical
|